Pregabalin Capsule
Product Images NDC 82804-274

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of the active ingredient pregabalin, showing its amino acid backbone with an isobutyl side chain and carboxylic acid group. This corresponds to the molecular structure of pregabalin.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with improvement percentages decreasing across increased pain improvement thresholds.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares two groups: one receiving Pregabalin 100 mg three times a day and one placebo group. Pregabalin treatment shows a higher percentage of patient improvement across the range compared to placebo.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared with placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph depicting the percentage of patients improved over percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis represents the percent improvement in pain from baseline, while the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph tracks patient improvement percentages across varying degrees of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different dosage groups in two studies labeled Study E1 and Study E3. The x-axis shows various doses including placebo and multiple treatment doses, while the y-axis represents the responder rate percentage ranging from 0% to 60%. Data points indicate higher responder rates with increasing doses compared to placebo in both studies.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting median seizure reduction percentage from baseline versus dose (mg/day) for four study groups labeled Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. The graph includes significant p-values for dose points, showing seizure reduction increasing with dose for each study.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar chart titled "Responder Rate (%)" comparing three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day with responder rates of 22.6%, 29.1%, and 40.6%, respectively. Sample sizes are 93 for Placebo, 103 for 2.5 mg/kg/day, and 96 for 10 mg/kg/day.*

FDA Label Image

Figure 10 (Pregabalin 11)

A Kaplan-Meier survival curve graph comparing Pregabalin to placebo. The x-axis represents time in days, ranging up to 180, while the y-axis shows the estimated percentage of subjects without LTR, from 0% to 100%. Two curves are shown: a solid line for Pregabalin and a dashed line for placebo, illustrating their respective survival probabilities over time.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin doses of 600 mg, 450 mg, and 300 mg daily against a placebo. The y-axis represents the percent of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from 0 to 100. Different line styles distinguish between doses and placebo.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph showing the percent of subjects improved over time from baseline to week 12 based on BOCF data. The x-axis represents percent improved from baseline through various time points, and the y-axis shows the percent of subjects improved. Two lines compare Pregabalin and Placebo, with Pregabalin consistently showing a higher percentage of subjects improved.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16, measured as Percent Improved from Baseline to Week 16 RCOF. Two lines are shown representing Pregabalin and Placebo groups, indicating the trend in percent improvement across varying thresholds of improvement percentages.*

FDA Label Image

82804-274-60 (Image 01)

Label for Pregabalin 100 mg capsules by Proficient Rx LP, containing 60 capsules. The label includes the NDC number 82804-274-60 and states prescription use only with a Schedule V control drug designation. Capsules are described as white to off-white powder in size "3" hard gelatin capsules with an orange opaque cap and body, imprinted with "SG" and "353." Manufacturer is ScieGen Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.